OROTECAN Trademark

Trademark Overview

On Monday, July 29, 2019, a trademark application was filed for OROTECAN with the United States Patent and Trademark Office. The USPTO has given the OROTECAN trademark a serial number of 88544233. The federal status of this trademark filing is ABANDONED - NO STATEMENT OF USE FILED as of Monday, August 29, 2022. This trademark is owned by Edison Oncology Holding Corp.. The OROTECAN trademark is filed in the Pharmaceutical Products category with the following description:

Pharmaceutical products in the nature of antineoplastic topoisomerase I inhibitors used for the prevention and treatment of cancer
orotecan

General Information

Serial Number88544233
Word MarkOROTECAN
Filing DateMonday, July 29, 2019
Status606 - ABANDONED - NO STATEMENT OF USE FILED
Status DateMonday, August 29, 2022
Registration Number0000000
Registration DateNOT AVAILABLE
Mark Drawing4000 - Illustration: Drawing with word(s) / letter(s) / number(s) in Block form
Published for Opposition DateTuesday, December 1, 2020

Trademark Statements

Goods and ServicesPharmaceutical products in the nature of antineoplastic topoisomerase I inhibitors used for the prevention and treatment of cancer

Classification Information

International Class005 - Pharmaceutical and veterinary preparations; sanitary preparations for medical purposes; dietetic substances adapted for medical use, food for babies; plasters, materials for dressings; material for stopping teeth, dental wax; disinfectants; preparations for destroying vermin; fungicides, herbicides.
US Class Codes005, 006, 018, 044, 046, 051, 052
Class Status Code6 - Active
Class Status DateWednesday, August 7, 2019
Primary Code005
First Use Anywhere DateNOT AVAILABLE
First Use In Commerce DateNOT AVAILABLE

Trademark Owner History

Party NameEdison Oncology Holding Corp.
Party Type20 - Owner at Publication
Legal Entity Type03 - Corporation
AddressMenlo Park, CA 94025
Party NameEdison Oncology Holding Corp.
Party Type10 - Original Applicant
Legal Entity Type03 - Corporation
AddressMenlo Park, CA 94025

Trademark Events

Event DateEvent Description
Monday, August 29, 2022ABANDONMENT NOTICE E-MAILED - NO USE STATEMENT FILED
Monday, August 29, 2022ABANDONMENT - NO USE STATEMENT FILED
Tuesday, April 26, 2022NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Monday, April 25, 2022SOU EXTENSION 2 GRANTED
Wednesday, January 26, 2022SOU EXTENSION 2 FILED
Friday, March 4, 2022NOTICE OF REVIVAL - E-MAILED
Friday, March 4, 2022SOU EXTENSION RECEIVED WITH TEAS PETITION
Friday, March 4, 2022PETITION TO REVIVE-GRANTED
Friday, March 4, 2022TEAS PETITION TO REVIVE RECEIVED
Monday, February 28, 2022ABANDONMENT NOTICE E-MAILED - NO USE STATEMENT FILED
Monday, February 28, 2022ABANDONMENT - NO USE STATEMENT FILED
Friday, July 23, 2021NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Thursday, July 22, 2021SOU EXTENSION 1 GRANTED
Thursday, July 15, 2021SOU EXTENSION 1 FILED
Thursday, July 22, 2021CASE ASSIGNED TO INTENT TO USE PARALEGAL
Thursday, July 15, 2021SOU TEAS EXTENSION RECEIVED
Tuesday, January 26, 2021NOA E-MAILED - SOU REQUIRED FROM APPLICANT
Tuesday, December 1, 2020OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
Tuesday, December 1, 2020PUBLISHED FOR OPPOSITION
Wednesday, November 11, 2020NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
Monday, October 26, 2020APPROVED FOR PUB - PRINCIPAL REGISTER
Friday, October 23, 2020TEAS/EMAIL CORRESPONDENCE ENTERED
Thursday, October 22, 2020CORRESPONDENCE RECEIVED IN LAW OFFICE
Thursday, October 22, 2020TEAS RESPONSE TO OFFICE ACTION RECEIVED
Thursday, April 23, 2020NOTIFICATION OF NON-FINAL ACTION E-MAILED
Thursday, April 23, 2020NON-FINAL ACTION E-MAILED
Thursday, April 23, 2020NON-FINAL ACTION WRITTEN
Wednesday, April 8, 2020TEAS/EMAIL CORRESPONDENCE ENTERED
Wednesday, April 8, 2020CORRESPONDENCE RECEIVED IN LAW OFFICE
Tuesday, April 7, 2020ASSIGNED TO LIE
Monday, March 30, 2020TEAS RESPONSE TO OFFICE ACTION RECEIVED
Wednesday, October 23, 2019NOTIFICATION OF NON-FINAL ACTION E-MAILED
Wednesday, October 23, 2019NON-FINAL ACTION E-MAILED
Wednesday, October 23, 2019NON-FINAL ACTION WRITTEN
Wednesday, October 23, 2019ASSIGNED TO EXAMINER
Wednesday, August 7, 2019NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
Thursday, August 1, 2019NEW APPLICATION ENTERED

Related Keywords

orotecan used prevention treatment cancer inhibitors topoisomerase products nature antineoplastic pharmaceutical